雷公藤提取物中主要物质基础及其抗肿瘤活性研究北大核心CSCD

为进一步阐明雷公藤中的主要物质基础,并评价其抗肿瘤活性。该研究采用柱层析、HPLC等技术,对雷公藤提取物进行研究。结果表明:(1)从雷公藤95%乙醇提取物中分离得到12个化合物,根据理化性质及波谱数据鉴定各化合物的结构分别为α,β-amyrenone(1)、3β-acetoxyolean-12-en-28-oic acid(2)、antriptolactone(3)、ω-hydroxypropioquaiacone(4)、3-(4-hydroxy-3-methoxyphenyl)-propenal(5)、3-methoxy-4-hydroxy phenylethanol(6)、vanillin(7)、3,4,5-三甲氧基苯酚(8)、对羟基苯甲酸(9)、对羟基苯甲醛(10)、vanillyl alcohol(11)、2,6-dimethxy-1,4-benzoquinone(12)。其中,化合物1、2、5、12为首次在该属植物中分离得到。(2)采用噻唑蓝(MTT)法对12个化合物进行抗SH-SY5Y细胞株、K562细胞株和Hel细胞株3种肿瘤细胞系细胞增殖活性的筛选,并对活性较好的化合物12进行Hoechst荧光染色和促凋亡作用的检测发现,化合物2、3、5、12具有一定的抗肿瘤活性,其中化合物12的抗肿瘤活性最为显著(SH-SY5Y细胞、Hel细胞、K562细胞的IC_(50)值分别为35.6、14.3、28.8μmol·L^(-1))。该研究结果进一步丰富了雷公藤的化学成分,发现了1个具有明显抗肿瘤活性的单体物质,为雷公藤的进一步开发提供了科学依据。     

Cyclophilin A binds to AKT1 and facilitates the tumorigenicity of Epstein-Barr virus by mediating the activation of AKT/mTOR/NF-κB positive feedback loop

The AKT/mTOR and NF-κB signalings are crucial pathways activated in cancers including nasopharyngeal carcinoma (NPC), which is prevalent in southern China and closely related to Epstein-Barr virus (EBV) infection. How these master pathways are persistently activated in EBV-associated NPC remains to be investigated. Here we demonstrated that EBV-encoded latent membrane protein 1 (LMP1) promoted cyclophilin A (CYPA) expression through the activation of NF-κB. The depletion of CYPA suppressed cell proliferation and facilitated apoptosis. CYPA was able to bind to AKT1, thus activating AKT/mTOR/NF-κB signaling cascade. Moreover, the use of mTOR inhibitor, rapamycin, subverted the activation of the positive feedback loop, NF-κB/CYPA/AKT/mTOR. It is reasonable that LMP1 expression derived from initial viral infection is enough to assure the constant potentiation of AKT/mTOR and NF-κB signalings. This may partly explain the fact that EBV serves as a tumor-promoting factor with minimal expression of the viral oncoprotein LMP1 in malignancies. Our findings provide new insight into the understanding of causative role of EBV in tumorigenicity during latent infection.     

Combinatorial effect of blueberry extracts and oxaliplatin in human colon cancer cells

The use of natural compounds to potentiate the effect of drugs and lower their adverse effects is an active area of research. The objective is to determine the effect of combined blueberry extracts (BE) and oxaliplatin (OX) in colon cancer cells. The results demonstrated that treatments of BE/OX showed inhibitory effects on HCT-116 cell and nontoxic effect on CCD-18Co normal colon cells. Flow cytometry analysis indicated that treatment with the BE, OX or in combination could induce G0/G1 cell cycle arrest, apoptosis, increase of reactive oxygen species, and induce loss of mitochondrial membrane potential in HCT-116 cells. Furthermore, after treatments, the expression of inflammatory cytokines was decreased, cyclin D1 and CDK4 were decreased; caspases-3 and 9 were activated; the Akt/Bad/Bcl-2 pathway was modulated. Moreover, the combination treatment had a considerably higher growth inhibitory effect on human colon cancer HCT-116 cells than that of BE or oxaliplatin alone. Our results showed that BE increased the anticolon cancer effect of OX making it an attractive strategy as adjuvant therapy to potentially reduce the adverse side effects associated with chemotherapeutic drugs.     

Long term experimental drought alters community plant trait variation,not trait means,across three semiarid grasslands

Plant and Soil - Mechanisms by which soil pH affects rice growth await further elucidation. We have used a Systems Biology approach to elucidate the nature of the damage caused by extreme pH to...     

Paecilomyces variotii extracts (ZNC) enhance plant immunity and promote plant growth

Plant and Soil - There are growing concerns regarding the restoration of karst rocky desertification (KRD) areas. However, the soil conditions and its residing microorganisms, which are essential...     

Characterization of proteins in different subcellular localizations for Escherichia coli K12

Knowing the comprehensive knowledge about the protein subcellular localization is an important step to understand the function of the proteins. Recent advances in system biology have allowed us to develop more accurate methods for characterizing the proteins at subcellular localization level. In this study, the analysis method was developed to characterize the topological properties and biological properties of the cytoplasmic proteins, inner membrane proteins, outer membrane proteins and periplasmic proteins in Escherichia coli (E. coli). Statistical significant differences were found in all topological properties and biological properties among proteins in different subcellular localizations. In addition, investigation was carried out to analyze the differences in 20 amino acid compositions for four protein categories. We also found that there were significant differences in all of the 20 amino acid compositions. These findings may be helpful for understanding the comprehensive relationship between protein subcellular localization and biological function     

CDKN1B Val 109 Gly variant is not related to risk of prostate cancer

Association between CDKN1B gene Val 109 Gly polymorphism and prostate cancer (PCa) susceptibility has been investigated in several studies but with inconsistent conclusions. We adopted odds ratios (ORs) and 95% confidence intervals (CIs) to assess the correlation between CDKN1B Val 109 Gly variant and PCa susceptibility. Moreover, we used in-silico tools to evaluate the relationship of CDKN1B expression and overall survival (OS) or disease free survival (DFS) time in PCa patients. The overall results demonstrated no association of the CDKN1B variant on PCa risk [allelic contrast (OR = 0.78, 95% CI = 0.45 − 1.35, P_{heterogeneity} = 0.038); GV vs VV (OR = 0.83, 95% CI = 0.56 − 1.25, P_{heterogeneity} = 0.253); GG vs VV (OR = 0.48, 95% CI = 0.23 − 1.01, P_{heterogeneity} = 0.161); GG+GV vs VV (OR = 0.75, 95% CI = 0.52 −1.08, P_{heterogeneity} = 0.132) and GG vs GV+VV (OR = 0.63, 95% CI = 0.25 − 1.11, P_{heterogeneity} = 0.152)]. In subgroup analysis by ethnicity and source of control, we also identified similar results. In-silico results showed that expression of CDKN1B was decreased in PCa tissue, especially in less advanced PCa (Gleason score = 6 or 7). No significant difference of OS or DFS time was indicated between the low and high expression of CDKN1B. Our present study showed evidence that CDKN1B Val 109 Gly variant is not related to PCa risk. Future studies with large sample size are needed to confirm this correlation in more details.